A 32-question patient survey at the 2024 Eczema Expo assessed treatment goals, therapy-switching patterns, and interest in a predictive molecular test among adults (and some pediatric caregivers) with atopic dermatitis (AD), with no comparator group and a cross-sectional design.
Among 43 participants, itch control (70%), skin clearance (58%), and safety (50%) were the top treatment priorities; 55% of systemic therapy users modified their first systemic due to inefficacy; and 94% of those open to a new systemic said they would use a molecular test to guide therapy selection.
Convenience sample from a single advocacy event (2024 Eczema Expo) likely skews toward more severe, treatment-experienced patients; very small sample (n=43) limits generalizability; cross-sectional design with recall bias and predominantly female respondents.
Most patients on systemic AD therapy still experience inadequate itch and skin-clearance control, driving frequent treatment switching—clinicians should prioritize these outcomes in shared decision-making and consider that patients are highly receptive to precision tools (e.g., molecular testing) to guide systemic therapy selection.
Explore related topics
